Clozapine re-exposure after dilated cardiomyopathy
Publication date
2017-05-27
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
No license information available
Abstract
A 63-year-old woman with diabetes type II and a history of breast cancer was treated with clozapine for her refractory schizophrenia. She developed a dilated cardiomyopathy with an ejection fraction of 25%, a life-threatening event. The cause of heart failure could be multifactorial, with clozapine, family history, chemotherapy, diabetes type II and/or lithium as possible contributing risk factors. Clozapine was discontinued and the patient was referred to a hospice. Two weeks later, her heart failure slowly improved. Subsequently, she became extremely psychotic with a severe decline in quality of life. Therefore, it was decided to restart clozapine under cardiac monitoring. The patient's psychotic symptoms improved and her heart failure status remained stable for more than a year. Thereafter, a small deterioration was seen in cardiac function. In this case, re-exposure to clozapine was successful for at least 2 years.
Keywords
Taverne, SDG 3 - Good Health and Well-being
Citation
Nederlof, M, Benschop, T W, de Vries Feyens, C A & Heerdink, E R 2017, 'Clozapine re-exposure after dilated cardiomyopathy', BMJ Case Reports, vol. 2017, 219652. https://doi.org/10.1136/bcr-2017-219652